Mosanna Therapeutics

Mosanna Therapeutics is a clinical-stage biotech company developing a novel pharmaceutical approach to treating obstructive sleep apnea (OSA), which affects an estimated 1 billion people globally. Its lead therapy, MOS118, is an easy-to-use nighttime nasal spray designed to restore the body's natural upper airway reflex during sleep — treating OSA as a neurological and muscular dysfunction rather than a purely mechanical problem. This positions MOS118 as a non-invasive alternative to CPAP and other mechanical treatments. The $80 million Series A was led by Pivotal bioVenture Partners and EQT Life Sciences, with co-leads Forbion, Broadview Ventures, and Norwest. MOS118 is currently in Phase 1 clinical trials, with the new funding advancing it through Phase 2. Mosanna has offices in Redwood City, California and Basel, Switzerland.